|
Type of Company:
Type:
|
Company
|
Ownership: |
Acquired |
Company Size: |
58 Employees In BC (58 Total)
58 In BC (58 Total)
|
Revenue: |
$46.70 Million CAD |
Year Founded: |
2000 |
Sector: |
Biotech/Life Sciences
Biotech/Life Sciences
|
Region: |
Lower Mainland / South Coast
Lower Mainland
|
Tags: |
pain, immuno-inflammatory, disease, ion-channel, therapeutics
|
Profile Views: |
1,488 Company Profile Views |
|
|
Zalicus Inc. discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. We apply our selective ion-channel modulation platform and our combination high throughput screening capabilities to discover innovative therapeutics for both our internal product pipeline and our collaborators.
Our drug discovery technology has identified Prednisporin, one of our most advanced clinical product candidates, on behalf of our partners at Fovea Pharmaceuticals (a division of Sanofi Aventis), and has also been seen as an important technology by our collaborators at Novartis and Amgen in support of their oncology research efforts.
|
|
|
Date |
Type |
Amount |
Investors |
Date |
Type |
Amount |
Investors |
|
|
Share This Company Profile |
|
Disclaimer: Company Profiles in the Tech Directory on T-Net are created, edited and maintained primarily by employees within individual companies, and are subject to continual change without notice and possible errors and/or omissions. Information within the pages of this Tech Directory is of a general nature intended only for informational purposes, and such information should not be relied upon. T-Net does not warrant or guarantee the quality, accuracy or completeness of such information and expressly disclaims liability for any loss, inconvenience or damages (including special, indirect or consequential damages) caused as a result of any errors in, or omissions from, such information. If you see an error, please let us know. Copyright T-Net. All rights reserved.
|
|